Literature DB >> 8992998

Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure.

S J Kent1, P D Greenberg, M C Hoffman, R E Akridge, M J McElrath.   

Abstract

Prior immunity to HIV-1 elicited by vaccination may modify subsequent responses upon exposure to infectious HIV-1. An HIV-1-uninfected person entered in a vaccine trial that included immunizations to HIV-1(LAI) envelope with a recombinant vaccinia vector and recombinant protein developed envelope-specific CD4+ T cell responses, including proliferative and cytolytic responses, but was not protected from a high risk HIV-1 exposure. CD4+ T cell clones derived from blood at the peak of vaccine-induced immunity recognized and lysed autologous target cells expressing four distinct regions within the HIV-1(LAI) envelope region; three of these CTL clones also recognized targets expressing envelope from a similar viral subtype, HIV-1(MN). The epitope specificity of CD4+ clone 9G8, recognizing both HIV-1(LAI) and HIV-1(MN) envelope, was within the 571-590 amino acid envelope region. Sequence analysis of the first infectious autologous strain revealed two amino acid mutations within this region. The 9G8 CTL clone induced by immunization failed to recognize targets expressing the corresponding CTL epitope from the infecting virus. Moreover, a peptide based on the epitope sequence of the infecting isolate antagonized the vaccine-induced CTL clone such that the CTL clone was no longer able to recognize the vaccine strain or HIV-1(MN) epitope. These findings suggest a potentially novel mechanism associated with vaccine failure whereby the infecting virus may not only escape from CTL activity, but also alter the ability of CTL to recognize other variants in an individual.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8992998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope.

Authors:  Philip J Norris; Jennifer D Stone; Nadezhda Anikeeva; John W Heitman; Ingrid C Wilson; Dale F Hirschkorn; Margaret J Clark; Howell F Moffett; Thomas O Cameron; Yuri Sykulev; Lawrence J Stern; Bruce D Walker
Journal:  Mol Immunol       Date:  2005-10-07       Impact factor: 4.407

3.  Enhanced cellular immunity in macaques following a novel peptide immunotherapy.

Authors:  S Chea; C J Dale; R De Rose; I A Ramshaw; S J Kent
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.

Authors:  L Mortara; F Letourneur; H Gras-Masse; A Venet; J G Guillet; I Bourgault-Villada
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice.

Authors:  Néstor Rubio-Infante; Dania O Govea-Alonso; Andrea Romero-Maldonado; Ana Lilia García-Hernández; Damaris Ilhuicatzi-Alvarado; Jorge A Salazar-González; Schuyler S Korban; Sergio Rosales-Mendoza; Leticia Moreno-Fierros
Journal:  Mol Biotechnol       Date:  2015-07       Impact factor: 2.695

6.  Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity.

Authors:  Shuping Wang; Rico Buchli; Jennifer Schiller; Jianen Gao; Rodney S VanGundy; William H Hildebrand; David D Eckels
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

7.  Substitutions in a major histocompatibility complex class II-restricted human immunodeficiency virus type 1 gp120 epitope can affect CD4+ T-helper-cell function.

Authors:  C Lekutis; N L Letvin
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Authors:  Uma Malhotra; Sarah Holte; Tuofu Zhu; Elizabeth Delpit; Claire Huntsberry; Alessandro Sette; Raj Shankarappa; Janine Maenza; Lawrence Corey; M Juliana McElrath
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus.

Authors:  Victoria Kasprowicz; Scott M Ward; Alison Turner; Alexandros Grammatikos; Brian E Nolan; Lia Lewis-Ximenez; Charles Sharp; Jenny Woodruff; Vicki M Fleming; Stuart Sims; Bruce D Walker; Andrew K Sewell; Georg M Lauer; Paul Klenerman
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.